Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2025-06-09
- Lead Sponsor
- Antengene Therapeutics Limited
- Target Recruit Count
- 98
- Registration Number
- NCT05205109
- Locations
- 🇦🇺
Calvary Mater Newcastle, Sydney, New South Wales, Australia
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
🇦🇺Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
- Conditions
- Solid TumorHematological Malignancy
- Interventions
- Drug: ATG-017+Nivolumab
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Antengene Therapeutics Limited
- Target Recruit Count
- 36
- Registration Number
- NCT04305249
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- Solid Tumor, Non-Hodgkin's Lymphoma
- Interventions
- Combination Product: ATG-019 + Niacin ER
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Antengene Therapeutics Limited
- Target Recruit Count
- 20
- Registration Number
- NCT04281420
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Antengene Therapeutics Limited
- Target Recruit Count
- 73
- Registration Number
- NCT03591965
- Locations
- 🇨🇳
Oncology Hospital of Haerbin Medical University, Harbin, Heilongjiang, China
🇨🇳China People PLA 81 Hospital, Nanjing, Jiangsu, China
🇨🇳West China Hospital Sichuan University, Chengdu, Sichuan, China